REGN5458 is a bispecific BCMA/CD3 T cell engaging antibody.
SparkCures ID | 351 |
---|---|
Developed By | Regeneron Pharmaceuticals |
Generic Name | REGN5458 |
Treatment Classifications | |
Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.